
Bora Lim MD
Assistant Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TexasRecent Contributions to PracticeUpdate:
- Novel Therapeutic Targets in the Management of Breast Cancer
- Residual Cancer Burden in TNBC Patients Receiving Neoadjuvant Chemotherapy
- Neoadjuvant Alpelisib Plus Nab-Paclitaxel for Triple-Negative Breast Cancer
- Panitumumab Plus Chemotherapy for Patients With Inflammatory Breast Cancer
- Atezolizumab, Cobimetinib, and Eribulin in Patients With Metastatic Inflammatory Breast Cancer
- TAK-228 Plus Hormonal Therapy for Metastatic, ER-Positive/HER2-Negative Breast Cancer